Abstract:The total synthesis of structurally complex natural products has challenged and inspired generations of chemists and remains an exciting area of active research. Despite their history as privileged bioactivity-rich scaffolds, the use of natural products in drug discovery has waned. This shift is driven by their relatively low abundance hindering isolation from natural sources and the challenges presented by their synthesis. Recent developments in biocatalysis have resulted in the application of enzymes for the construction of complex molecules. From the inception of the Narayan lab in 2015, we have focused on harnessing the exquisite selectivity of enzymes alongside contemporary small molecule-based approaches to enable concise chemoenzymatic routes to natural products.We have focused on enzymes from various families that perform selective oxidation reactions. For example, we have targeted xyloketal natural products through a strategy that relies on a chemo- and site-selective biocatalytic hydroxylation. Members of the xyloketal family are characterized by polycyclic ketal cores and demonstrate potent neurological activity. We envisioned assembling a representative xyloketal natural product (xyloketal D) involving a biocatalytically generated ortho-quinone methide intermediate. The non-heme iron (NHI) dependent monooxygenase ClaD was used to perform the benzylic hydroxylation of a resorcinol precursor, the product of which can undergo spontaneous loss of water to form an ortho-quinone methide under mild conditions. This intermediate was trapped using a chiral dienophile to complete the total synthesis of xyloketal D.A second class of biocatalytic oxidation that we have employed in synthesis is the hydroxylative dearomatization of resorcinol compounds using flavin-dependent monooxygenases (FDMOs). We anticipated that the catalyst-controlled site- and stereoselectivity of FDMOs would enable the total synthesis of azaphilone natural products. Azaphilones are bioactive compounds characterized by a pyranoquinone bicyclic core and a fully substituted chiral carbon atom. We leveraged the stereodivergent reactivity of FDMOs AzaH and AfoD to achieve the enantioselective synthesis of trichoflectin enantiomers, deflectin 1a, and lunatoic acid. We also leveraged FDMOs to construct tropolone and sorbicillinoid natural products. Tropolones are a structurally diverse class of bioactive molecules characterized by an aromatic cycloheptatriene core bearing an α-hydroxyketone moiety. We developed a two-step biocatalytic cascade to the tropolone natural product stipitatic aldehyde using the FDMO TropB and a NHI monooxygenase TropC. The FDMO SorbC obtained from the sorbicillin biosynthetic pathway was used in the concise total synthesis of a urea sorbicillinoid natural product.Our long-standing interest in using enzymes to carry out C-H hydroxylation reactions has also been channeled for the late-stage diversification of complex scaffolds. For example, we have used Rieske oxygenases to hydroxylate the tricyclic core common to paralytic shellfish toxins. The systemic toxicity of these compounds can be reduced by adding hydroxyl and sulfate groups, which improves their properties and potential as therapeutic agents. The enzymes SxtT, GxtA, SxtN, and SxtSUL were used to carry out selective C-H hydroxylation and O-sulfation in saxitoxin and related structures. We conclude this Account with a discussion of existing challenges in biocatalysis and ways we can currently address them.

Chemoenzymatic synthesis of small molecule human therapeutics.

Chemo-enzymatic synthesis of natural products and their analogs

Biocatalysis for Green Chemistry and Drug Development

One-pot chemoenzymatic syntheses of non-canonical amino acids

Biocatalysis for the Synthesis of Pharmaceuticals and Pharmaceutical Intermediates

Enantioselective Transformations in the Synthesis of Therapeutic Agents

Extending the application of biocatalysis to meet the challenges of drug development

Biocatalysis in drug discovery and development

State-of-the-Art Biocatalysis

Chemoenzymatic approaches for exploring structure–activity relationship studies of bioactive natural products

Biocatalysis for Drug Discovery and Development

Catalyzing the future: recent advances in chemical synthesis using enzymes

Recent Advances in Biocatalysis for Drug Synthesis

Current Progress in the Chemoenzymatic Synthesis of Natural Products

Synthesis at the Interface of Chemistry and Biology

Combining chemistry and protein engineering for new-to-nature biocatalysis

The importance of synthetic chemistry in the pharmaceutical industry

Application of Biocatalysis in the Synthesis of Enantiopure Drugs

Chemoenzymatic Total Synthesis of Natural Products

Chemoenzymatic synthesis planning by evaluating the synthetic potential in biocatalysis and chemocatalysis

From nature to industry: Harnessing enzymes for biocatalysis